Protagonist Therapeutics Inc
XNAS:PTGX
| Market Cap (Intraday) | 9.79B |
| Current PE | 118.06 |
| Forward PE | 31.73 |
| 2yr Forward PE | N/A |
| 10-Day MA | $147.10 |
| 50-Day MA | $142.86 |
| 200-Day MA | $107.29 |
Protagonist Therapeutics Inc Stock, XNAS:PTGX
7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160
United States of America
Phone: +1.510.474.0170
Number of Employees: 126
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.